{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:14:46Z","timestamp":1793056486710,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Enfortumab vedotin plus pembrolizumab (EVP) has shown promising efficacy in locally advanced or metastatic urothelial carcinoma (la\/mUC), but real-world data in Japanese patients are limited. We assessed the safety and early efficacy of EVP, with a focus on cutaneous adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 48 Japanese patients with la\/mUC treated with first-line EVP at 12 centers between November 2024 and March 2025. Clinical data, AEs, and tumor responses were collected. Cutaneous AEs were evaluated for onset, severity, and management. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patients\u2019 median age was 76\u00a0years, and 89.6% were cisplatin-ineligible. All patients experienced treatment-related AEs, with 39.6% having grade\u00a0\u22653 events. Cutaneous AEs occurred in 60.4%, including 18.8% with grade\u00a0\u22653 rash and two cases of Stevens\u2013Johnson syndrome. The median time to discontinuation due to AEs was 14\u00a0days. The overall response rate was 39.6%, and the disease control rate was 69%, rising to 87% among 38 evaluable patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EVP demonstrated favorable early efficacy in Japanese patients but was associated with frequent early discontinuation due to AEs, particularly cutaneous toxicity. Early skin care and interdisciplinary management are essential. These findings support EVP use while emphasizing AE management and patient-centered care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf182","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:48:13Z","timestamp":1763574493000},"page":"234-240","source":"Crossref","is-referenced-by-count":10,"title":["Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-852X","authenticated-orcid":false,"given":"Kosuke","family":"Iwatani","sequence":"first","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei University Kashiwa Hospital , 163-1 Kashiwashita, Kashiwa-shi, Chiba, Tokyo 277-0004 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei University the 3rd Hospital , 4-11-1 Izumi-honcho, Komae-shi, Tokyo 201-8601 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juria","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, JR Tokyo General Hospital , 2-1-3 Yoyogi, Shibuya-ku, Tokyo 151-8528 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Machida Municipal Hospital , 2-15-41 Asahimachi, Machida-shi, Kanagawa 194-0023 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei University Katsushika Medical Cener , 6-41-2 Aoto, Katsushika-ku, Tokyo 125-8506 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Tokyo-Kita Medical Center , 4-17-56 Akabanedai, Kita-ku, Tokyo 115-0053 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimu","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Tokyo Metropolitan Hiroo General Hospital , 2-34-10 Ebisu, Shibuya-ku, Tokyo 150-0013 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Kayano","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Ota Memorial Hospital , 455-1 Ojima-cho, Ota-shi, Gunma 373-8585 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Tsukuba Memorial Hospital , 1187-299 Kaname, Tsukuba-shi, Ibaraki 300-2622 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Atsugi Municipal Hospital , 1-16-36 Mizuhiki, Atsugi-shi, Kanagawa 243-8588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Fuji City General Hospital , 50 Takashima-cho, Fuji-shi, Shizuoka 417-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4684","authenticated-orcid":false,"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Waki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jikei University Kashiwa Hospital , 163-1 Kashiwashita, Kashiwa-shi, Chiba 277-0004,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-8640","authenticated-orcid":false,"given":"Jun","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei University Kashiwa Hospital , 163-1 Kashiwashita, Kashiwa-shi, Chiba, Tokyo 277-0004 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2026021308512111800_ref1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"2026021308512111800_ref2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021308512111800_ref3","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026021308512111800_ref4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jjco\/hys235","article-title":"Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate","volume":"43","author":"Funakoshi","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2026021308512111800_ref5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026021308512111800_ref6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/iju.15362","article-title":"Summary of the clinical practice guidelines for upper tract urothelial carcinoma 2023 by the Japanese Urological Association","volume":"31","author":"Mori","year":"2024","journal-title":"Int J Urol"},{"key":"2026021308512111800_ref7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00262-024-03910-3","article-title":"Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: A systematic review and network meta-analysis","volume":"74","author":"Yanagisawa","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026021308512111800_ref8","doi-asserted-by":"publisher","first-page":"1326715","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer","volume":"14","author":"Brower","year":"2024","journal-title":"Front Oncol"},{"key":"2026021308512111800_ref9","doi-asserted-by":"publisher","first-page":"595.e1","DOI":"10.1016\/j.urolonc.2025.05.016","article-title":"Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis","volume":"43","author":"Gazzoni","year":"2025","journal-title":"Urol Oncol"},{"key":"2026021308512111800_ref10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/cup.14689","article-title":"Enfortumab vedotin-induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature","volume":"51","author":"Sport","year":"2024","journal-title":"J Cutan Pathol"},{"key":"2026021308512111800_ref11","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1111\/1346-8138.16567","article-title":"Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption","volume":"49","author":"Hasegawa","year":"2022","journal-title":"J Dermatol"},{"key":"2026021308512111800_ref12","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of Dermatologic Events Associated with the Nectin-4-directed antibody-drug conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist."},{"key":"2026021308512111800_ref13","doi-asserted-by":"publisher","first-page":"e254692","DOI":"10.1136\/bcr-2023-254692","article-title":"Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab","volume":"16","author":"McCormick","year":"2023","journal-title":"BMJ Case Rep"},{"key":"2026021308512111800_ref14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdcr.2023.05.004","article-title":"Pembrolizumab-induced lichenoid dermatitis treated with dupilumab","volume":"37","author":"Park","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2026021308512111800_ref15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of &gt;2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"2026021308512111800_ref16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"2026021308512111800_ref17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: Response, survival and safety analysis from a multicentre real-world Japanese cohort","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026021308512111800_ref18","doi-asserted-by":"publisher","first-page":"102326","DOI":"10.1016\/j.clgc.2025.102326","article-title":"Impact of initial relative dose intensity on tumor response and survival outcomes in Enfortumab Vedotin monotherapy for previously treated advanced urothelial carcinoma: A real-world analysis from a Multicenter study","volume":"23","author":"Miyake","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"2026021308512111800_ref19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/jjco\/hyaf060","article-title":"Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study","volume":"55","author":"Urabe","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026021308512111800_ref20","doi-asserted-by":"publisher","first-page":"102148","DOI":"10.1016\/j.clgc.2024.102148","article-title":"Organ-specific tumor response to Enfortumab Vedotin for metastatic urothelial carcinoma: A Multicenter retrospective study","volume":"22","author":"Minato","year":"2024","journal-title":"Clin Genitourin Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/234\/65396760\/hyaf182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/234\/65396760\/hyaf182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:51:31Z","timestamp":1770990691000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/2\/234\/8328252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2026,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf182","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,19]]}}}